Tuesday, December 5, 2023
Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.
Leader, Chronic Myeloid Leukemia Program
Memorial Sloan Kettering Cancer Center
Professor, Weill Cornell Medicine
New York, New York
Clinical Assistant Professor of Medicine
Adjunct Clinical Professor of Nursing
Director, Advanced Practice and Clinical Integration
The University of Arizona Cancer Center
Tucson, Arizona
This activity has been peer reviewed and the reviewer has no relevant financial relationships.
Physicians - maximum of 0.75 AMA PRA Category 1 Credit(s)™
ABIM Diplomates - maximum of 0.75 ABIM MOC points
Nurses - 0.75 ANCC Contact Hour(s) (0.75 contact hours are in the area of pharmacology)
IPCE - 0.75 Interprofessional Continuing Education (IPCE) credit
This activity is intended for physicians and nurse specialists in hematology/oncology.
The goal of this activity is for learners to be better able to understand the long-term nature of later-line therapies for the treatment of chronic myeloid leukemia (CML), and to help them develop a patient-centric approach to management that includes quality of life considerations, adverse event management, and shared decision-making (SDM) to ensure optimal outcomes and long-term adherence to therapy.
Upon completion of this activity, participants will:
Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.
Leader, Chronic Myeloid Leukemia Program
Memorial Sloan Kettering Cancer Center
Professor, Weill Cornell Medicine
New York, New York
Clinical Assistant Professor of Medicine
Adjunct Clinical Professor of Nursing
Director, Advanced Practice and Clinical Integration
The University of Arizona Cancer Center
Tucson, Arizona
This activity has been peer reviewed and the reviewer has no relevant financial relationships.
This activity was planned by and for the healthcare team, and learners will receive 0.75 Interprofessional Continuing Education (IPCE) credit for learning and change.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Awarded 0.75 contact hour(s) of nursing continuing professional development for RNs and APNs; 0.75 contact hours are in the area of pharmacology.
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability
and acceptance of continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the
activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit(s)™, you must receive a minimum score of 75% on the post-test.
Follow these steps to earn CME/CE credit*:
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it.
Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print
out the tally as well as the certificates from the CME/CE Tracker.
*The credit that you receive is based on your user profile.
CME / ABIM MOC / CE Released: 9/29/2023
Valid for credit through: 9/29/2024, 11:59 PM EST
processing....
Please answer the questions below to self-assess your knowledge. Answering these questions again after the activity will allow you to see what you learned.
